Placeholder Banner

BIO’s Statement on the Confirmation of Andrei Iancu to Lead the U.S. Patent and Trademark Office

February 5, 2018

Washington, D.C. (February 5, 2018) – The following statement may be attributed to BIO President & CEO James Greenwood:

“I congratulate Andrei Iancu on his Senate confirmation to fill the position of Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (PTO).

“The position of PTO Director is extraordinarily important, as it oversees a federal agency that is an indispensable element of the continued economic growth and innovation of American enterprise.

“Strong and reliable patents are the lifeblood of the biotechnology industry. They are critical in ensuring a steady stream of capital to biotechnology companies developing innovative medicines and more sustainable, bio-based energy and agricultural products. And they are essential to the technology transfer process that leads from inventions in the lab to products on the shelves. 

“I look forward to engaging with Director Iancu and his staff as BIO continues to push for balanced reforms to curb abusive anti-patent practices, protect the ability of patent owners to defend their inventions and businesses against infringement, and promote greater predictability and certainty of patent rights as a basis for investment in innovation.”

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…